What is Avalo Therapeutics's net investment in lease?

Avalo Therapeutics (AVTX) reported net investment in lease of $268K in Q1 2026.

How has Avalo Therapeutics's net investment in lease changed year-over-year?

Avalo Therapeutics's net investment in lease decreased by 56.4% year-over-year, from $615K to $268K.

What is the long-term trend for Avalo Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), Avalo Therapeutics's net investment in lease has grown at a -18.2% compound annual growth rate (CAGR), from $917K to $336K.

Avalo Therapeutics AVTX Net Investment in Lease

Net Investment in Lease at other companies

XencorXNCR

——

AbCellera Biologics Inc.ABCL

——

AnaptysBio, Inc.ANAB

——

Absci CorporationABSI

——

ImmunomeIMNM

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's net investment in lease?: Avalo Therapeutics (AVTX) reported net investment in lease of $268K in Q1 2026.
How has Avalo Therapeutics's net investment in lease changed year-over-year?: Avalo Therapeutics's net investment in lease decreased by 56.4% year-over-year, from $615K to $268K.
What is the long-term trend for Avalo Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), Avalo Therapeutics's net investment in lease has grown at a -18.2% compound annual growth rate (CAGR), from $917K to $336K.